Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors

  • Technology appraisal guidance
  • TA407
  • Published: 
Download guidance (PDF)

3 Evidence

The appraisal committee considered evidence submitted by Novartis and a review of this submission by the evidence review group (ERG). It also considered evidence received from patient and professional groups. See the committee papers for full details of the evidence.